Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.
For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.
We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.
Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.
We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.
Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.
The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.
As part of World AIDS Day Dr. Fauci would like to thank community members that work with the Division of AIDS (DAIDS) funded networks and programs for their time and effort.
People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape.
In this edition we explore the intersection of faith and HIV with perspectives from HVTN Core staff and Faith Ambassadors, share information about the launch of a new marketing campaign aimed at supporting phase 1 enrollment, and share news of a new program aimed at increasing the scientific leadership of HVTN investigators.